Show simple item record

dc.creatorBix, Gregory J.
dc.creatorWright, Sarah
dc.creatorGriswold-prenner, Irene
dc.date.accessioned2019-06-17T17:11:07Z
dc.date.available2019-06-17T17:11:07Z
dc.date.issued2016-06-07
dc.identifier.urihttp://hdl.handle.net/1969.1/177150
dc.description.abstractThe application reports that perlecan domain V (DV) or the LG3 domain thereof reduces deposition and toxicity of Aβ peptide, the major component of plaques in Alzheimer's disease. Methods of using DV, LG3 and related molecules in treatment of amyloidogenic diseases, particularly Alzheimer's disease, are provided.en
dc.languageeng
dc.publisherUnited States. Patent and Trademark Office
dc.rightsPublic Domain (No copyright - United States)en
dc.rights.urihttp://rightsstatements.org/vocab/NoC-US/1.0/
dc.titleUse of perlecan domain V in treating amyloidogenic diseaseen
dc.typeUtility patenten
dc.format.digitalOriginreformatted digitalen
dc.description.countryUS
dc.contributor.assigneeTHE Texas A&M UNIVERSITY SYSTEM
dc.identifier.patentapplicationnumber13/519949
dc.date.filed2011-01-06
dc.publisher.digitalTexas A&M University. Libraries
dc.subject.cpcprimaryA61K 38/39


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record